iTeos Therapeutics, Inc.

Ownership Transactions Reported by 22 Insiders

Symbol
ITOS on Nasdaq
Location
321 Arsenal Street, Bldg 312, Floor 3, Suite 301, Watertown, MA

Insiders trading volume in the past year

iTeos Therapeutics, Inc. executives and other stock owners filed with the SEC include:

Name Relationship Holdings Value Past Year Net Change Change % Report Date
Ra Capital Management, L.P. Former 10% Owner $137M +$100M +270% May 10, 2024
Boxer Capital, LLC Other* $51.6M May 10, 2024
Ansbert Gadicke 10%+ Owner $37.5M Jan 4, 2022
Mpm Bioventures 2018, L.P. 10%+ Owner $22.9M Jan 4, 2022
MPM BioVentures 2014, L.P. 10%+ Owner $22.9M Jan 4, 2022
Matthew Call Chief Operating Officer $1.15M Mar 7, 2024
Matthew Gall Chief Financial Officer $506K +$38.6K +8.27% Nov 19, 2024
Michel Detheux Chief Executive Officer $493K Aug 8, 2024
David Feltquate Chief Medical Officer $363K Dec 6, 2024
Yvonne McGrath Chief Scientific Officer $259K Mar 7, 2024
Jill DeSimone Director Jun 11, 2024
Tony W. Ho Director Jun 11, 2024
Detlev Biniszkiewicz Director Jun 9, 2022
Davis Aaron I. Director Jun 11, 2024
Robert Iannone Director Jun 11, 2024
David K. Lee Director Jun 11, 2024
Derek DiRocco Director Jun 13, 2023
David Hallal Director Jun 11, 2024
Matthew Roden Director Jun 9, 2022
Timothy Van Hauwermeiren Director Jun 11, 2024
Joanne Jenkins Lager Chief Medical Officer Mar 9, 2023
Ann D. Rhoads Director Jun 11, 2024

Recent Insider Transactions by Companies or Individuals for iTeos Therapeutics, Inc.

Insider Symbol Class Transaction % Value $ * Price $ Shares Shares Owned Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.